YANGLING, China, Nov. 25 /Xinhua-PRNewswire/ -- Worldwide Biotech & Pharmaceutical Company has received positive response from Mr. Zeng Qinghong, Vice-President of the P.R. of China (''President Zeng’’), for its accomplishments in the research of the Hepatitis C Virus (HCV).
President Zeng visited Yangling Daiying Biotech & Pharmaceutical (Group) Co., Ltd. (''Yangling DAIYING’’), WWBP’s China company, on November 5th, 2005, accompanied by the deputy director of Chinese State Food & Drug Administration and Provincial Governor, Secretariat and other senior officers of the local government of Shannxi province. During his visit, President Zeng expressed strong interest in WWBP’s break-through researches -- “Intact HCV Culturing System and its applications in prevention and treatment of Hepatitis C.’'
''China should greatly support the development of hi-technologies with original intellectual property rights (IPR), in order to demonstrate the competitive status of our original IPR in the international world,’' President Zeng stressed after visiting Yangling DAIYING’s research and manufacturing facilities.
''The visit of President Zeng and other senior officers greatly encouraged us and lifted the moral of our staff. We understand this represents great recognition from the government and the central government on our contributions to the development of original IPR,’' Ms. GUO Wenxia, the President & Chief Executive Officer of Yangling DAIYING, thus evaluated, ''President Zeng’s encouragement enhances our faith in continuing our researches pioneering in the world HCV study area. We believe it is our responsibility to utilize our research abilities to benefit the world.’'
About Worldwide Biotech and Pharmaceutical Company
Worldwide Biotech & Pharmaceutical Co. (''WWBP’’) is a hi-tech biotech company with top-ranking pharmaceutical R&D abilities; Good Manufacturing Practices (GMP) licensed manufacturing facilities and well-established marketing network in China and Southeast Asia. The product range of WWBP covers Hepatitis C Virus (HCV) products, diagnostic medicines and Over-The- Counter (OTC) drugs. WWBP currently possesses 35,940 square meter land and 5,359 square meter GMP standard facilities. With strong pharmaceutical R&D abilities, especially in HCV field, WWBP has been known as the first biotech company in the world to hold the technology of culturing intact HCV in vitro by cell culture. Its principle project, ''The intact hepatitis C virus (HCV) and method for culturing HCV in vitro by cell culture,’' was awarded Chinese Patent by the China Patent Bureau and the prestigious China Patent Golden Medal by the World Intellectual Property Organization and China Patent Bureau. The medal is the only one issued for achievement in the biomedical sciences during the past 10 years. WWBP has achieved a GMP production scale level of 10,000 ml for concentrated HCV virus and 10 grams HCV antigen per month, which is expected to bring WWBP considerable gross sales revenue each year and greatly strengthen the company’s R&D on anti-HCV drug screen system and HCV human vaccine. WWBP had successfully reached two merger agreements with pharmaceutical companies in China, both of which have scalable production and well-established sales network and the acquiring is expected to be finished before the end of 2005. The acquisitions will strengthen WWBP’s R&D abilities and production scale, as well as extend its marketing network throughout China and Southeast Asia. WWBP has been working closely with pharmaceutical research institutes, and has established sound connections with both central & local governments.
About Mr. Zeng Qinghong
Zeng Qinghong was elected Vice-President of the People’s Republic of China on March 15, 2003. He is now member of the Standing Committee of the Political Bureau of the CPC Central Committee and member of the Secretariat of the CPC (Communist Party of China) Central Committee. He was member of the 15th CPC Central Committee, an alternate member of its political bureau and member of its Secretariat. He is member of the 16th CPC Central Committee, member of the Standing Committee of its Political Bureau, and member of the Secretariat of the CPC Central Committee.
http://www.china.org.cn/english/PP-e/48927.htm
Safe Harbor
Information in this news release or on this website may contain statements about future expectations, plans, prospects or performance of Worldwide Biotech & Pharmaceutical Co. that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. The words or phrases “can be,” “expects,” “may affect,” “believed,” “estimate,” “project,” and similar words and phrases are intended to identify such forward-looking statements. Worldwide Biotech & Pharmaceutical Co. cautions you that any forward-looking information provided by or on behalf of Worldwide Biotech & Pharmaceutical Co. is not a guarantee of future performance. None of the information on this website constitutes an offer to sell securities or investment advice of any kind, and visitors should not base their investment decisions on information contained in this website. Worldwide Biotech & Pharmaceutical Co.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Worldwide Biotech & Pharmaceutical Co.'s control. In addition to those discussed in Worldwide Biotech & Pharmaceutical Co.'s press releases, public filings, and statements by Worldwide Biotech & Pharmaceutical Co.'s management, including, but not limited to, Worldwide Biotech & Pharmaceutical Co.'s estimate of the sufficiency of its existing capital resources, Worldwide Biotech & Pharmaceutical Co.'s ability to raise additional capital to fund future operations, Worldwide Biotech & Pharmaceutical Co.'s ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Worldwide Biotech & Pharmaceutical Co.'s capability to be awarded contracts. All such forward- looking statements are current only as of the date on which such statements were made. Worldwide Biotech & Pharmaceutical Co. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
For more information, please contact: Worldwide Biotech and Pharmaceutical Company Ivy Liu Mobile: +86-29-8819-3339 Email: wwbp@worldwidebio.com
Worldwide Biotech and Pharmaceutical Company
CONTACT: Ivy Liu of Worldwide Biotech and Pharmaceutical Company,+86-29-8819-3339 or wwbp@worldwidebio.com
